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In the alarming context of rising bacterial antibiotic resistance, there is an urgent need to discover new antibiotics or 
increase and/or enlarge the activity of those currently in use. In this article, aminoguanidine and dihydrotriazine derivatives 
were designed, synthesized and evaluated in terms of their antibacterial and antifungal activities. Most of the synthesized 
compounds showed potent inhibitory activities against different bacteria and one fungus with minimum inhibitory 
concentrations (MICs) ranging from 1 to 64 μg/mL, which obviously better than the positives control drug. The compound 
23a showed the best antibacterial activities, whose MIC value was 1 μg/mL against eight strains. The cytotoxic activity of 
the compound 4c, 8a and 23a were assessed in Human liver cancer cells. The preliminary docking results imply that 
compounds 21b and 23a possibly display their antibacterial activity through the interaction with DHFR protein by targeting 
residues of the active cavities of DHFR. 
Keywords: Aminoguanidine, Antibacterial activities, Antifungal activities, Cytotoxicity, Dihydrotriazine 
Numerous research groups throughout the world are 
currently involved in an urgent search for novel 
antibacterial and antifungal agents to overcome the 
emergence of new infectious diseases and the 
increasing number of multidrug-resistant microbial 
pathogens
1,2
. According to the World Health 
Organization (WHO), if nothing is done, the world will 
enter a post antibiotic era, in which current infections 
and minor wounds will be able to kill once again. 
Methicillin-resistant S. aureus (MRSA) is a major 
pathogen causing both hospital and community 
acquired infections. Among these organisms, MRSA 
alone accounts for nearly one-half of the deaths 
attributed to antibiotic-resistant infections
3
. 
Aminoguanidine derivatives have recently captured the 
attention of numerous researchers because of their 
diverse range of biological properties, including their 
antibacterial
4
, antifungal
5
,
 
and anti-inflammatory 
activities
6
. 1,3,5-triazine derivatives have been reported 
to exhibit a wide range of interesting biological 
properties including anticancer, anti-HIV and 
antimicrobial activities
7-10
. The 1,2,3-triazoles are 
known for several biological activities such as 
antibacterial, antiviral and anti-inflammatory
11-13
. 
Recently, the concept of hybrid molecules has 
proved to be the most interesting topic in medicinal 
chemistry, where two or more pharmacophores are 
linked covalently resulting in one molecule
14-16
. Two 
units of the final molecule may act on different targets 
to exert dual drug action or one part can counter 
balance the side effects caused by another part. In our 
previous work, we reported the identification of 
aminoguanidine and dihydrotriazine derivatives, and 
demonstrated that all of the compounds belonging to 
this series showed outstanding bacteriostatic activity 
against Gram-positive bacteria, as exemplified by 
compounds A, B , and D (MIC = 0.5 or 32 μg/mL). 
Kumar Deepak et al. reported that compound C  
(Fig. 1) exhibited potent activity against 
Mycobacterium tuberculosis H37Rv strain with 
MIC99 values ranging from 0.3 μg/mL in vitro
17
. As a 
part of our ongoing studies toward the development of 
novel antibacterial agents, here we proposed to link 
aminoguanidine or dihydrotriazine and triazole 
entities together and synthesized novel derivatives. 
These two scaffolds were joined covalently into one 
—————— 
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single derivative in anticipation that the hybrid may 
show potent antibacterial and antifungal activities. 
 
Materials and Methods 
 
Chemistry 
Melting points were determined in open capillary 
tubes and are uncorrected. Reaction courses were 
monitored by TLC on silica gel-precoated F254 
Merck plates. Developed plates were examined with 
UV lamps at wavelengths of 254 nm. 
1
H-NMR and 
13
C-NMR spectra were measured on a BURKER 
NMR spectrometer at 300 MHz and 126 MHz  
while using TMS as the internal standard. Mass 
Spectrometry was measured on anAXIMA-CFR plus 
(Shimadzu, Japan) MALDI TOF/TOF spectrometer. 
The other raw materials and solvents were purchased 
from their respective suppliers and underwent no 
further purification. Distilled water was self-prepared 
in our laboratory. 
 
General procedures for the synthesis of 4a-c, 8a-b, 12a and 17a 
The hydroxybenzaldehyde, 4-formylbenzoic  
acid, 6-benzyloxynaphthalene, vanilline or 
hydroxyacetophenone was treated with propargyl 
bromide to get the compounds 2, 6, 10 and 15 , the 
cycloaddition of azide group and terminal alkyne  
via click reaction gave different triazole-based 
compounds 3, 7, 11 and 16 as depicted in  
(scheme 1)
17
, Ketone derivatives or aldehyde 
derivatives were dissolved in absolute ethanol  
(10-20 mL), aminoguanidine bicarbonate (1 eq) and 
catalytic amounts of hydrochloric acid were added
18
. 
The reaction mixtures were heated at reflux for 24 h. 
The solvent was evaporated under reduced pressure 
and the crude product was purified by silica gel 
column chromatography (dichloromethane/methanol, 
20:1) to afford the desired compounds as white solid. 
The yield, melting point and spectral data of each 
compound are given below. 
 
(E)-2-(4-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)benzylidene)hydrazine-1-carboximidamide (4a) 
Yield 62%; m.p. 68-70°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.86 (s, 1H, NH), 8.32 (s, 1H, CH=N), 
8.11 (s, 1H, Ar-H), 7.77 (d, J = 25.3 Hz, 5H, NH and 
Ar-H), 7.49 (s, 2H, Ar-H), 7.29 (s, 1H, Ar-H), 7.11  
(s, 2H, Ar-H), 5.73 (s, 2H, CH2), 5.21 (s, 2H, CH2). 
13
C NMR (126 MHz, DMSO-d6) δ 160.31, 155.87, 
146.93, 143.04, 134.49, 134.24, 132.83, 132.45, 
129.67, 128.40, 126.85, 125.72, 115.43, 61.64, 50.57. 
MS (MALDI-TOF) m/z 418 (M+1). 
(E)-2-(1-(4-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)phenyl)ethylidene)hydrazine-1-carboximidamide 
(4b) 
Yield 55%; m.p. 155-156°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.10 (s, 1H, NH), 8.30 (s, 1H, Ar-H), 
7.93 (d, J = 8.8 Hz, 2H,Ar-H), 7.72 (d, J = 2.0 Hz, 
3H, NH), 7.49 (dd, J = 8.3, 2.1 Hz, 1H, Ar-H), 7.28 
(d, J = 8.4 Hz, 1H, Ar-H), 7.06 (d, J = 8.9 Hz, 2H, 
CH2), 5.74 (d, J = 12.7 Hz, 3H, Ar-H), 5.21 (s, 2H, 
CH2), 2.31 (s, 3H, CH3). MS (MALDI-TOF) m/z 432 
(M+1)]. 
 
(E)-2-(4-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)-3-methoxybenzylidene)hydrazine-1-carboximidamide 
(4c) 
Yield 58%; m.p. 196-197°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.72 (s, 1H, NH), 8.30 (s, 1H, CH=N), 
8.08 (s, 1H, Ar-H), 7.73 (d, J = 2.1 Hz, 3H, NH), 
7.60-7.46 (m, 3H, Ar-H), 7.32-7.16 (m, 3H, Ar-H), 
5.75 (d, J = 12.3 Hz, 2H, CH2), 5.18 (s, 2H,CH2), 3.80 
(s, 3H, OCH3). MS (MALDI-TOF) m/z 448 (M+1). 
 
 
 
Fig. 1 — Previously reported antibacterial compounds 
BAI et al.: ACTIVITY EVALUATION OF AMINOGUANIDINE OR DIHYDROTRIAZINE DERIVATIVES 
 
 
303 
  
 
 
Scheme 1 — Synthetic route of compounds 4a-c, 8a-b, 12a, 13a-b 17a, 21a-b and 23a. Reagents and conditions: (A) Propargyl bromide, 
DMF, K2CO3, 35-40°C, 10 h; (B) 1-(Azidomethyl)-2,4-dichlorobenzene, Sodium ascorbate, CuSO4.5H2O, DMF:H2O (1:1), RT, 20 h;  
(C) Aminoguanidine bicarbonate, EtOH, HCl, 78°C, 24 h; (D) Moroxydine hydrochloride or metformin hydrochloride, AcOH, 120°C,  
4-8 h; (E) DMF-DMA, DMF, 80°C, 12 h; (F) Acetylacetone, AcOH, CH3COONH4, 80°C, 12 h; and (G) Orthoboric acid, Na2CO3, DME, 
H2O, 85°C, 4 h 
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(E)-2-(3-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)benzylidene)hydrazine-1-carboximidamide (8a) 
Yield 65%; m.p. 108-110°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.92 (s, 1H, NH), 8.34 (s, 1H, CH=N), 
8.14 (d, J = 2.0 Hz, 1H, Ar-H), 7.96-7.57 (m, 5H, NH 
and Ar-H), 7.55-7.44 (m, 1H, Ar-H), 7.42-7.23  
(m, 3H, Ar-H), 7.11 (d, J = 2.6 Hz, 1H, Ar-H), 5.73 
(d, J = 2.1 Hz, 2H, CH2), 5.20 (d, J = 2.0 Hz, 2H, 
CH2). 
13
C NMR (126 MHz, DMSO-d6) δ 158.76, 
155.96, 146.92, 143.16, 135.35, 134.50, 134.25, 
132.85, 132.45, 130.29, 129.65, 128.39, 125.66, 
121.62, 117.72, 112.94, 61.65, 50.57. MS (MALDI-
TOF) m/z 418 (M+1). 
 
(E)-2-(1-(3-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)phenyl)ethylidene)hydrazine-1-carboximidamide 
(8b) 
Yield 60%; m.p. 95-97°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.19 (s, 1H, NH), 8.30 (s, 1H, Ar-H), 
7.82 (s, 3H, NH), 7.72 (d, J = 1.9 Hz, 1H, Ar-H), 7.62 
(s, 1H, Ar-H), 7.49 (dd, J = 5.7, 2.6 Hz, 2H, Ar-H), 
7.39-7.26 (m, 2H, Ar-H), 7.11 (d, J = 8.0 Hz, 1H,  
Ar-H), 5.73 (s, 2H, CH2), 5.22 (s, 2H, CH2), 2.34  
(s, 3H, CH3). 
13
C NMR (126 MHz, DMSO-d6) δ 
158.51, 156.58, 151.90, 143.30, 138.78, 134.50, 
134.24, 132.85, 132.44, 129.86, 129.64, 128.39, 
125.66, 120.10, 61.59, 50.56. MS (MALDI-TOF) m/z 
432 (M+1).  
 
(E)-2-((6-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl) 
methoxy)naphthalen-2-yl)methylene)hydrazine-1-carboximidamide 
(12a)  
Yield 68%; m.p. 190-192°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 12.03 (s, 1H, NH), 8.36 (s, 1H, , CH=N), 
8.29 (s, 1H, Ar-H), 8.16 (d, J = 10.0 Hz, 2H, Ar-H), 
7.95-7.70 (m, 6H, NH and Ar-H), 7.57 (s, 1H, Ar-H), 
7.47 (dd, J = 8.3, 2.1 Hz, 1H, Ar-H), 7.27 (dd, J = 14.2, 
8.6 Hz, 2H, Ar-H), 5.75 (d, J = 10.1 Hz, 2H, CH2), 
5.29 (s, 2H, CH2). 
13
C NMR (126 MHz, DMSO-d6) δ 
157.53, 155.86, 147.50, 143.08, 135.82, 134.49, 
134.25, 132.84, 132.46, 130.51, 129.69, 128.61, 
128.39, 127.76, 125.79, 124.10, 119.80, 108.23, 61.67, 
50.58. MS (MALDI-TOF) m/z 468 (M+1). 
 
(1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl(E)-4-((2-
carbamimidoylhydrazono)methyl)benzoate (17a) 
Yield 55%; m.p. 246-247°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 12.13 (s, 1H, NH), 8.33 (s, 1H, CH=N), 
8.24 (s, 1H, Ar-H), 8.07-7.95 (m, 5H, NH and Ar-H), 
7.88 (s, 2H, Ar-H), 7.72 (d, J = 2.0 Hz, 1H, Ar-H), 
7.49 (dd, J = 8.3, 2.1 Hz, 1H, Ar-H), 7.31 (d, J = 8.3 
Hz, 1H, Ar-H), 5.75 (d, J = 12.3 Hz, 2H, CH2), 5.42 
(s, 2H, CH2). MS (MALDI-TOF) m/z 447 (M+1). 
General procedures for the synthesis of 13a-b 
Intermediate 11 and Metformin hydrochloride were 
refluxed in glacial acetic acid at 120°C for 4-6 h. The 
whole processes of the reactions were traced by TLC. 
The solvent was removed under reduced pressure. 
The crude products were purified by column 
chromatography (dichloromethane : methanol = 20 : 1)
19
. 
 
6-(6-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy) 
naphthalen-2-yl)-N2,N2-dimethyl-3,6-dihydro-1,3,5-triazine-
2,4-diamine (13a) 
Yield 45%; m.p. 108-110°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 8.86 (d, J = 14.1 Hz, 2H, NH2), 8.35  
(s, 1H, Ar-H), 7.90 (d, J = 8.4 Hz, 2H, Ar-H), 7.81  
(s, 1H, Ar-H), 7.73 (d, J = 2.1 Hz, 1H, Ar-H), 7.59-7.45 
(m, 3H, Ar-H), 7.28 (dd, J = 19.7, 8.7 Hz, 2H, Ar-H), 
5.94 (s, 1H, NH), 5.75 (d, J = 10.3 Hz, 2H, CH2), 5.27 
(s, 2H, CH2), 3.16 (d, J = 5.2 Hz, 3H, CH3), 3.06 (s, 4H, 
CH and CH3). 
13
C NMR (126 MHz, DMSO-d6) δ 
157.82, 156.95, 156.32, 143.12, 136.26, 134.79, 134.50, 
134.26, 132.85, 132.49, 130.18, 129.65, 128.38, 128.15, 
125.76, 125.33, 124.86, 119.83, 107.76, 62.89, 61.62, 
50.57, 37.37. MS (MALDI-TOF) m/z 523 (M+1). 
 
4-(6-((1-(2,4-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy) 
naphthalen-2-yl)-6-morpholino-1,4-dihydro-1,3,5-triazin-2-
amine (13b) 
Yield 50%; m.p. 100-102°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 9.41 (s, 1H, NH2), 9.14 (s, 1H, NH2), 8.37 
(s, 1H, CH), 7.89 (dd, J = 8.6, 5.6 Hz, 2H, Ar-H), 7.81 
(s, 1H, Ar-H), 7.71 (d, J = 1.8 Hz, 1H, Ar-H), 7.51 (dt,  
J = 8.2, 5.2 Hz, 4H, Ar-H), 7.32 (d, J = 8.3 Hz, 1H, Ar-H), 
7.24 (dd, J = 9.0, 2.1 Hz, 1H, Ar-H), 5.99 (s, 1H, NH), 
5.75 (d, J = 10.3 Hz, 2H, CH2), 5.27 (s, 2H, CH2), 3.64 
(s, 8H, CH2). 
13
C NMR (126 MHz, DMSO-d6) δ 158.17, 
156.99, 155.63, 143.11, 135.89, 134.83, 134.50, 134.27, 
132.84, 132.50, 130.21, 129.65, 128.37, 128.18, 125.76, 
125.40, 124.90, 119.85, 107.76, 66.07, 62.78, 61.62, 
50.58, 44.96. MS (MALDI-TOF) m/z 562 (M+1). 
 
General procedures for the synthesis of 21a-b 
Intermediate 19 was synthesized according to the 
reported method
20
. To a solution of the enaminone 19 
in glacial acetic acid, acetylacetone and ammonium 
acetate were added. The reaction mixture was heated 
under reflux for 3 h. After cooling and pouring into 
ice-water, the intermediate 20 obtained was filtered 
and washed with petroleum ether than with water and 
finally crystallized from ethanol
21
. 
 
(E)-2-(1-(6-(2,4-Dichlorophenyli-2-methylpyridin-3-yl) 
ethylidene)hydrazine-1-carboximidamide i21ai 
Yield 60%; m.p. 228-230°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.40 (s, 1H, NH), 7.91 (d, J = 8.0 Hz, 1H, 
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Ar-H), 7.82 (s, 3H, NH), 7.78-7.75 (m, 1H, Ar-H),  
7.61-7.55 (m, 3H, Ar-H), 2.60 (s, 3H, CH3), 2.38  
(s, 3H, CH3). 
13
C NMR (126 MHz, DMSO-d6) δ 156.69, 
155.97, 154.51, 152.97, 137.92, 136.96, 134.36, 133.64, 
133.36, 132.65, 129.83, 128.10, 122.14, 24.00, 19.21. 
MS (MALDI-TOF) m/z 336 (M+1). 
 
(E)-2-(1-(6-(4-Bromophenyl)-2-methylpyridin-3-yl)ethylidene) 
hydrazine-1-carboximidamide (21b) 
Yield 58%; m.p. 185-186°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.32 (s, 1H, NH), 8.12 (d, J = 8.7 Hz, 
4H, Ar-H), 7.90 (s, 3H, NH), 7.82 (s, 1H, Ar-H), 7.63 
(s, 1H, Ar-H), 2.41 (s, 3H, CH3), 2.30 (s, 3H, CH3). 
MS (MALDI-TOF) m/z 346 (M+1). 
 
General procedures for the synthesis of 23a 
Bromoacetophenone, the corresponding boronic 
acid, tetrakis (triphenylphosphine) palladium (0) and 
sodium carbonate in 1:1 dimethoxyethane:water (6 mL) 
was heated at 85°C for 4 h, and the solvents were 
evaporated to dryness. The residue was sonicated for 
15 min with 50 mL of EtOAc and filtered. Silica gel 
was added to the filtrate, and the solvents were 
evaporated to dryness. The residue was applied to a 
silica gel column and eluted using EtOAc-hexane as 
the mobile phase to give the intermediate 22
22
. 
 
(E)-2-(1-(2',4'-Dichloro-[1,1'-biphenyl]-4-yl)ethylidene) 
hydrazine-1-carboximidamide(23a) 
Yield 55%; m.p. 98-100°C. 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.16 (s, 1H, NH), 8.08 (d, J = 43.8 Hz, 
3H, NH), 7.80 (t, J = 8.3 Hz, 2H, Ar-H), 7.59-7.40 
(m, 4H, Ar-H), 7.28 (d, J = 2.1 Hz, 1H, Ar-H), 2.53 
(s, 3H, CH3). 
13
C NMR (126 MHz, DMSO-d6) δ 
156.58, 151.59, 139.21, 138.64, 137.01, 133.63, 
133.11, 132.79, 129.80, 129.64, 128.21, 127.17, 
15.11. MS (MALDI-TOF) m/z 321 (M+1). 
 
Evaluation of antibacterial activity in vitro 
The micro-organisms used in the present study 
were S. aureus 4220, E. Coli 1942, S. mutans 3289 
and C. Albicans 7535. The strains of multidrug-
resistant clinical isolates were methicillin-resistant  
S. aureus (MRSA CCARM 3167 and 3506) and 
quinolone-resistant S. aureus (QRSA CCARM 3505 
and 3519). Clinical isolates were collected from 
various patients hospitalized in several clinics. Test 
bacteria were grown to mid-log phase in Muellere 
Hinton broth (MHB) and diluted 1000-fold in the 
same medium. The bacteria of 10
5
 CFU/mL were 
inoculated into MHB and dispensed at 0.2 mL/well in 
a 96-well microtiter plate. As positive controls, 
oxacillin and norfloxacin were used. Test compounds 
were prepared in DMSO, the final concentration of 
which did not exceed 0.05%. A two-fold serial 
dilution technique was used to obtain final 
concentrations of 64-0.25 µg/mL. The MIC was 
defined as the concentration of a test compound that 
completely inhibited bacteria growth during 24 h 
incubation at 37°C. Bacteria growth was determined 
by measuring the absorption at 650 nm using a 
microtiter enzyme-linked immunosorbent assay 
(ELISA) reader. All experiments were carried out 
three times
19
. 
 
Cytotoxicity on human cells 
The cytotoxicity test of selected compounds was 
measured through the colorimetric MTT assay. 
Human liver cancer cells (BEL 7402) suspension in 
DMEM medium supplemented with 10% FBS and 
antimycotic was added in 96 well microplates at  
1.8 × 10
4
 cells/well. A variety of concentrations of the 
test compounds (200, 100, 50, 25, 12.5, 6.25, 3.125, 
1.625 µM/L) dissolved by distilled 10% DMSO was 
added to each well. Incubation for 24 h at 37°C under 
5% CO2, 2.5 mg/mL of MTT solution was added to 
each well. Further, the plate was incubated for 4 h. 
Then, the medium was removed and the resulting 
formazan crystals were dissolved with 100 µL 
DMSO. After shaking 10 min, the optical density was 
measured at 570 nm using a microtiter ELISA reader. 
The selected compounds were used as a positive 
control, whereas untreated cells were used as negative 
controls. The IC50 values were defined as the 
concentrations inhibiting 50% of cell growth. All 
experiments were performed in triplicate
19
. 
 
Results and Discussion 
 
In vitro antibacterial activity  
The in vitro antibacterial activities of the 
synthesized compounds were evaluated using a  
96-well microtiter plate and a serial dilution method 
to obtain the minimum inhibitory concentrations 
(MICs) for different strains (including multidrug-
resistant clinical isolates). Gatifloxacin, moxifloxacin, 
norfloxacin, and oxacillin were used as positive 
controls for antibacterial activity, and fluconazole and 
itraconazole were used as positive controls  
for antifungal activity, and the results are shown in 
(Table 1). Most of the newly synthesized compounds 
exhibited potent inhibitory activities against the 
different bacteria and single fungus tested in the 
current study with MICs in the range of 1-64 µg/mL. 
It is noteworthy that compound 23a exhibited the 
greatest activities of all of the compounds prepared in 
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the current study with MIC value of 1 μg/mL against 
eight strains, making its potency comparable to those 
gatifloxacin and moxifloxacin. In terms of its activity 
towards the fungus C. albicans 7535, compound 23a 
displayed the strongest activity of all of the 
compounds synthesized in the current study with an 
MIC value of 1 µg/mL, making it equipotent to 
fluconazole. Furthermore, compound 23a was 
determined to be 4-fold more potent than 
moxifloxacin (MIC = 4 µg/mL) and 8-fold more 
potent than Gatifloxacin (MIC = 8 µg/mL) towards 
QRSA CCARM 3505. Against MRSA CCARM 3506 
(Table 2), compounds 8a and 13a were equipotent to 
the positive controls gatifloxacin (MIC = 2 µg/mL).  
Analysis of these results revealed several structure 
activity relationships. A comparison of the potency of 
compounds 13a and 13b revealed that isosteric 
replacement with a morpholine or dimethylamine group 
at the N-position of the dihydro-1,3,5-triazine ring 
generally did not affect the antimicrobial activity.  
It is also noteworthy that compound 21a, bearing a  
2,4-dichloro-substituted phenyl ring, showed excellent 
antimicrobial activities. These results therefore, provide 
further evidence that the inclusion of a 2,4-dichloro-
substituted benzene ring is critical to the activity of these 
compounds, which is consistent with the results obtained 
for a previously reported series of aminoguanidine and 
dihydrotriazine derivatives 
19,23
. A comparison of the 
results for compounds 21a, 21b and 23a revealed that the 
inclusion of a benzene ring led to an increase in 
antimicrobial activity. Taken together, these results 
suggest that compound 23a could be used as hits for the 
development of a suitable lead compound for further 
investigation, especially for novel antifungal agents. 
 
Cytotoxicity study 
To determine whether the compounds synthesized 
in the current study were selectively toxic towards 
bacteria, we evaluated the cytotoxicities of several 
representative compounds (4c, 8a, 23a) using a 
standard technique. As shown in the (Table 3), 
Table 1 — Inhibitory activity (MIC, g/mL) of compounds 4a-c, 
8a-b, 12a, 13a-b, 17a, 21a-b and 23a against various bacteria 
Compound Gram-positive  
strains 
 Gram-negative 
strains 
 Fungus 
 4220a 3289b 1924c 7535d 
4a 4 8 8 4 
4b 4 4 8 4 
4c 8 16 8 8 
8a 2 4 8 4 
8b 4 4 4 4 
12a 8 2 4 8 
13a 4 8 4 4 
13b 4 8 4 4 
17a 32 64 32 16 
21a 4 16 4 4 
21b 16 16 16 16 
23a 1 1 1 1 
Gatifloxacin 0.25 0.25 2 0.5 
Moxifloxacin 0.25 0.25 2 0.5 
Fluconazole n.d n.d n.d 1 
Itraconazole n.d n.d n.d 0.6 
aStaphylococcus aureus RN 4220.  
bStreptococcus mutans 3289.  
cEscherichia coli KCTC 1924.  
dCandida albicans 7535; n.d.: Not determined 
 
Table 2 — Inhibitory activity (MIC, µg/mL) of compounds 4a-c, 
8a-b, 12a, 13a-b, 17a, 21a-b and 23a against clinical isolates of 
multidrug-resistant Gram-positive strains 
 
Compound 
Multidrug-resistant Gram-positive strains 
MRSA  QRSA 
3167a 3506b 3505c 3519d 
4a 8 4 8 8 
4b 8 4 8 8 
4c 8 8 8 16 
8a 4 2 4 4 
8b 4 4 4 8 
12a 4 4 8 8 
13a 4 2 4 4 
13b 4 4 4 4 
17a 32 32 32 32 
21a 8 4 8 8 
21b 16 16 16 16 
23a 1 1 1 1 
Gatifloxacin 2 2 8 4 
Moxifloxacin 1 1 4 4 
Norfloxacin 8 4 >64 >64 
Oxacillin >64 >64 1 1 
aMethicillin-resistant S. aureus CCARM 3167.  
bMethicillin-resistant S. aureus CCARM 3506. 
cQuinolone-resistant S. aureus CCARM 3505.  
dQuinolone-resistant S. aureus CCARM 3519. 
 
Table 3 — Antibacterial activity and cytotoxicity for 4c, 8a ,  
and 23a 
 Test organisms 4c 8a 23a 
MIC 
(µg/mL) 
IC50
a 
(µmol/L) 
S. aureus 4220 
MRSA 3519 
BEL7402b 
8 
16 
6.13 
2 
4 
11.02 
1 
1 
6.95 
aIC50 is the concentration required to inhibit cell growth by  
50%. Data represent the average of three independent experiments 
running in triplicate. Variation was generally between 5–10%. 
bHuman liver cancer cells. 
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compound 4c exhibited weaker activity than 23a 
against the different bacteria, in spite of its slight 
greater cytotoxicity than 23a, comparably indicating 
that the promising antibacterial activity of these 
compounds may not be due to their cytotoxicity, but 
some unknown mechanism of action. 
 
In silico docking study 
To rationalize the observed antibacterial activity 
and understand the possible mechanism of action of 
these compounds, a docking investigation was 
undertaken. The crystal structure data (S. aureus 
DHFR) were obtained from the protein data bank 
(PDB ID: 3fra)
24,25
. Enzyme structures were checked 
for missing atoms, bonds and contacts. Hydrogen 
atoms were added to the enzyme structure. Water 
molecules and bound ligands were manually 
deleted
26
. Preferred coordination modes of 21b and 
23a with dihydrofolate reductase (DHFR) protein are 
presented in (Fig. 2). Fragment A of 21b is bound into 
the active site, in which the benzene ring shows 
Amide-Pi stacked interaction with Phe 92. The chloro 
atom of 21b interacted with Leu 5 via a pi-alkyl bond. 
Fragment B of 23a is bound into the active site where 
the aminoguanidine group shows attractive charge 
interaction with Asp 27 and the methyl group of 23a 
formed alkyl bond with Leu 5 and Phe 92, the 
benzene ring of 23a formed a pi-alkyl bond with Leu 
20, comparably indicated its more potent activity than 
that of 21b. The preliminary docking results imply 
that compounds 23a and 21b possibly display their 
antibacterial activity through the interaction with 
DHFR protein by targeting residues of the active 
cavities of DHFR. 
 
Conclusion 
In summary, we have synthesized aminoguanidine 
or dihydrotriazin derivatives and evaluated their 
antibacterial and antifungal activities. Compound 23a 
showed the highest levels of activity against eight 
strains with a MIC value of 1 µg/mL. Preliminary 
docking study showed that these compounds have a 
 
 
Fig. 2 — Docking result of compound 21b and 23a. (A) Key residues in binding site surrounding 21b; (B) 2D molecular docking 
modeling of compound 21b with 3fra; (C) Key residues in binding site surrounding 23a; and (D) 2D molecular docking modeling of 
compound 23a with 3fra. 
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good interaction with the active cavities of DHFR, 
possibly exhibit their potency via inhibiting DHFR.  
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